An outbreak of a new coronavirus causing severe respiratory disease (COVID-19) was first reported in China and rapidly spread worldwide. Clinical spectrum changes from asymptomatic infection to severe illness and even death, and no specific treatment is currently available. A range of antiviral, antimalarial and antibiotic agents are being used. We report a case of a COVID-19 patient that progressed to severe disease requiring intubation and intensive care. We performed mesenchymal stem cell (MSC) transplantation considering the signs showing persistent excessive immune response and deterioration despite all supportive and drug therapies. The two rounds of transplantation did not result in any severe complications and was well-tolerated. Clinical signs were improved. The use of MSC therapy may be considered for compassionate use in selected patients.
Local anesthetics are used to anesthetize surface areas in several procedures. The history of anesthesia exposure has been established as an important factor for correct diagnosis. When they are used excessively, some systemic side effects such as methemoglobinemia, respiratory failure, cardiovascular arrhythmias, or neurological manifestations may occur. Methemoglobinemia which usually presents with nonspecific symptoms is a serious entity. It is a rare but severe side effect of anesthetics. We herein present a case of methemoglobinemia due to local anesthesia with prilocaine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.